Tarsus Pharmaceuticals, Inc. TARS
75.69
(0.27)
(0.36%)
as of 25 Sep
- Market cap
- $3.6B
- P/E
- 0.0×
Follow TARS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (13.68%) | (13.96%) | (23.39%) | (28.35%) |
+8 more TTM periods Free account |
|
| (8.40%) | (8.92%) | (14.14%) | (17.82%) | ||
ROIC |
0.00% | (96.77%) | 0.00% | (988.67%) | |
Return on Tangible Assets |
(11.43%) | (11.73%) | (16.66%) | (20.79%) | |
Average Days of Receivables |
59.18 | 79.95 | 70.44 | 74.11 | |
Free Cash Flow per Share |
1.29 | (0.73) | (0.53) | (1.35) | |
Free Cash Flow |
56.00 | (31.54) | (22.31) | (57.54) | |
Capital Expenditures |
(18.15) | (15.09) | (9.86) | (3.57) | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
8.53% | (2.03%) | (1.49%) | (6.67%) | |
Accounts Receivable Turnover |
7.65 | 5.90 | 6.68 | 7.00 | |
Accounts Payable Turnover |
0.69 | 0.69 | 2.38 | 0.31 | |
Inventory Turnover |
9.88 | 9.58 | 8.78 | 7.39 | |
Average Days of Payables |
359.59 | 252.60 | 194.93 | 1,530.48 | |
Days of Inventory on Hand |
39.21 | 47.86 | 52.01 | 56.72 | |
Tax Rate |
0.13 | 0.05 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.46% | 13.51% | 14.25% | 17.25% | |
Selling, General and Administrative Expense of Revenue |
86.82% | 89.47% | 94.67% | 99.88% | |
Share Based Compensation of Revenue |
8.55% | 8.74% | 9.24% | 9.51% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.60) | 0.34 | 0.19 | 0.66 | |
Depreciation/Fixed assets |
(0.05) | (0.15) | (0.26) | (0.64) | |
Capex/Depreciation |
16.55 | 5.78 | 3.21 | 0.98 | |
Revenue per Share |
13.97 | 12.46 | 10.80 | 8.59 | |
Operating CF per Share |
1.71 | (0.38) | (0.30) | (1.27) | |
Capex per Share |
(0.42) | (0.35) | (0.24) | (0.08) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.01 | |
Net Profit Margin |
(7.67%) | (9.02%) | (14.72%) | (22.17%) |
Columns are period end dates